Compare HMY & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HMY | RGEN |
|---|---|---|
| Founded | 1950 | 1981 |
| Country | South Africa | United States |
| Employees | 34350 | N/A |
| Industry | Precious Metals | Medical/Dental Instruments |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.7B | 8.1B |
| IPO Year | N/A | 1995 |
| Metric | HMY | RGEN |
|---|---|---|
| Price | $14.30 | $110.25 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 11 |
| Target Price | $16.00 | ★ $175.64 |
| AVG Volume (30 Days) | ★ 4.5M | 811.6K |
| Earning Date | 02-04-2016 | 04-28-2026 |
| Dividend Yield | ★ 1.20% | N/A |
| EPS Growth | N/A | ★ 286.96 |
| EPS | N/A | ★ 0.86 |
| Revenue | N/A | ★ $141,236,000.00 |
| Revenue This Year | $40.34 | $14.31 |
| Revenue Next Year | $22.08 | $14.41 |
| P/E Ratio | ★ $15.60 | $132.98 |
| Revenue Growth | N/A | ★ 35.10 |
| 52 Week Low | $12.57 | $102.97 |
| 52 Week High | $26.04 | $175.77 |
| Indicator | HMY | RGEN |
|---|---|---|
| Relative Strength Index (RSI) | 33.92 | 30.20 |
| Support Level | $13.53 | N/A |
| Resistance Level | $15.65 | $132.51 |
| Average True Range (ATR) | 0.64 | 4.68 |
| MACD | -0.11 | 0.43 |
| Stochastic Oscillator | 18.68 | 2.57 |
Harmony Gold Mining Co Ltd is engaged in gold mining and related activities, including exploration, extraction, and processing. The group's primary product is gold bullion, produced at operations in South Africa and Papua New Guinea. Gold byproducts include uranium and silver. Strategic projects such as the Wafi-Golpu Project in the New Guinea Mobile Belt, the Eva Copper Project in the Mt Isa Inlier, Queensland, Australia, and the MAC Copper acquisition position the company as a gold-copper producer. The company operates across South Africa, Papua New Guinea, and Australia.
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.